GHENT, BELGIUM and OSLO, NORWAY--(Marketwire - Nov 21, 2012) - Ablynx (EURONEXT BRUSSELS: ABLX) and Algeta ASA (OSE: ALGETA) announce a research collaboration to evaluate a novel Targeted Thorium ...

OSLO, NORWAY--(Marketwired - Jun 11, 2013) - Algeta ASA (OSE: ALGETA) announces a collaboration with Australian biotechnology company Avipep Pty Ltd to evaluate a novel Targeted Thorium Conjugate (TTC ...

Algeta ASA, announces it has entered into a technology access agreement with Lumiphore, Inc. that could enable Algeta to develop the next generation of cancer-targeting alpha-pharmaceuticals. The ...

German pharmaceutical group Bayer offered to buy Norway's Algeta, its partner for a new prostate cancer treatment, for $2.4 billion, a 27 percent premium to the stock's last close, Algeta said on ...

Algeta ASA, has announced that it has entered into an exclusive research, development and commercialization agreement with Affibody (Stockholm, Sweden) to develop tumor-targeting alpha-pharmaceuticals ...

- ALSYMPCA Study Designed to Evaluate Alpharadin for the Treatment ofBone Metastases in Prostate Cancer Patients Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces thatit is to ...

OSLO/FRANKFURT (Reuters) - German drug firm Bayer (GER:BAYN) has clinched a $2.9 billion (1.7 billion pounds) deal to take over Norwegian cancer drug maker Algeta (OSL:ALGETA) after being tendered ...

Add Yahoo as a preferred source to see more of our stories on Google. BERLIN (AP) -- Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based ...

FRANKFURT/OSLO (Reuters) - Bayer has won backing from the board of Algeta , its partner for a new prostate cancer treatment, for an increased $2.9 billion offer to buy the Norwegian company. The cash ...

OSLO/LONDON (Reuters) - Bayer (BAYGn.DE) has offered to pay $2.4 billion for Norway's Algeta (Oslo:ALGETA.OL - News), its partner for a new prostate cancer treatment, at a 27 percent premium to the ...

Shares in Algeta, the Norwegian pharmaceutical company that specialises in cancer medicine, are up more than 30 per cent this morning after it confirmed in a statement to the Oslo stock exchange that ...

Algeta and Ablynx enter into a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies® Oslo, Norway, and Ghent, ...